Merck earnings top estimates amid solid demand for Keytruda cancer drug
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
Leerink Partners Reiterates Outperform Rating on Merck (MRK)
November 1, 2024 7:20 AM EDTLeerink Partners analyst Joseph P. Schwartz reiterated an Outperform rating on Merck (NYSE: MRK).
The analyst comments "Bottom Line: Gardasil remained the primary topic for Merck (MRK, OP) earnings and continues to weigh on the stock, which is trading at a 13.6 PE multiple, below most of its... More
